



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

**INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

1

of

2

Complete If Known	
Application Number	10/030,350
Filing Date	January 7, 2002
First Named Inventor	Anne Clark
Art Unit	1651
Examiner Name	Susan Marie Hanley
Attorney Docket Number	NBI-108US

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
SMH	A1	6,562,836 B1	05-13-2003	Szarek, et al.	
SMH	A2	2004/0198832 A1	10-07-2004	Szarek, et al.	
SMH	A3	2004/0248876 A1	12-09-2004	Szarek, et al.	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>3</sup>
		Country Code <sup>4</sup> -Number <sup>5</sup> -Kind Code <sup>6</sup> (if known)				
SMH	A4	WO 93/03714 A2	03-04-1993	The Upjohn Company		
	A5	WO 94/22437 A2,A3	10-13-1994	Queen's Univ. at Kingston		
	A6	WO 94/27602 A1	12-08-1994	Cortex Pharmaceuticals, Inc.		
	A7	WO 96/28187 A1	09-19-1996	Queen's Univ. at Kingston		
	A8	WO 96/37612 A1	11-28-1996	Pfizer, Inc.		
	A9	WO 98/11923 A1	03-26-1998	Baylor College of Medicine		
	A10	WO 99/40909 A1	08-19-1999	Neurochem, Inc.		
	A11	WO 00/64420 A2	11-02-2000	Queen's Univ. at Kingston		
	A12	WO 00/71101 A2,A3	11-30-2000	Queen's Univ. at Kingston		
SMH	A13	WO 01/03680 A2	01-18-2001	Isis Innovation Limited		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
SMH	A14	Copani, A., et al. "Activation of metabotropic glutamate receptors protects cultured neurons against apoptosis induced by $\beta$ -amyloid peptide." <i>Mol. Pharmacol.</i> 1995 May; 47(5):890-7.	
SMH	A15	Hutchings, R., et al. "The effect of excitotoxin antagonists on ibotenic acid-induced alteration of APP mRNA hippocampal expression" <i>Journal of Pharmacy and Pharmacology.</i> 1995 Dec; 47(12B):1131.	
SMH	A16	Pache, D.M., et al. "Effect of selective excitatory amino acid antagonists on excitotoxin-induced changes in APP mRNA expression." <i>Pharmacology Reviews and Communications.</i> 1999; 10(3):205-12.	
SMH	A17	Schwarz, R., et al. "Excitatory aminoacid antagonists provide a therapeutic approach to neurological disorders." <i>Lancet.</i> 1985 Jul 20; 2(8447):140-3.	

Examiner Signature

Date Considered

4/30/05



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	2	of	2	Attorney Docket Number	NBI-108US
-------	---	----	---	------------------------	-----------

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	B1	Westerman, C.T., et al. "A comparison of amyloid deposition in human and transgenic mouse islets of langerhans transplanted into nude mice." <i>Amyloid and Amyloidosis</i> 1998, Proc. Int. Symp. Amyloidosis, 8 <sup>th</sup> , Rochester, Minn; 645-647. <i>cited by Examiner</i>	
SMA	B2	"Use of metabotropic agonists in progressive neurodegenerative diseases", <i>Expert Opinion on Therapeutic Patents</i> , 1995; 5(5):491-3.	

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup>Applicant's unique citation designation number (optional). <sup>3</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	<i>Anne Clark</i>	Date Considered	4/30/05
--------------------	-------------------	-----------------	---------